Banca de QUALIFICAÇÃO: NADJA MARIA DA COSTA MELO

Uma banca de QUALIFICAÇÃO de MESTRADO foi cadastrada pelo programa.
STUDENT : NADJA MARIA DA COSTA MELO
DATE: 27/07/2021
TIME: 08:00
LOCAL: videoconferência
TITLE:

ACTIVITY OF HYDROETHANOLIC EXTRACT FROM Cereus jamacaru P.DC. (mandacaru) IN DNBS-INDUCED INFLAMMATORY BOWEL DISEASE MODEL

KEY WORDS:

Colitis; IBD, Cactaceae; phytochemical

PAGES: 118
BIG AREA: Ciências Biológicas
AREA: Farmacologia
SUMMARY:

Inflammatory bowel diseases (IBD) are chronic inflammatory and reductive diseases whose pathogenesis is associated with genetic alterations and a defect or increase in the sensitivity of the mucosa to antigens in the intestinal lumen. The drugs available for the treatment of IBD can cause potentially serious adverse effects, showing the need to search for new therapeutic strategies. In this sense, natural products rich in bioactive compounds with anti-inflammatory activity stand out, such as mandacaru (Cereus jamacaru P. DC.). This cactus is a native species of the caatinga vegetation of the semi-arid northeast, with popular use in several diseases, and can be considered promising to treat intestinal inflammatory processes. This research aimed to evaluate the activity of the hydroethanolic extract of Cereus jamacaru P. D.C. in a model of intestinal inflammation in rats. The stems were collected in the city of Jucurutu/RN, the spines removed, cut and dried in an oven at 55ºC for 24hrs, then they were ground, going through maceration with ethanol and obtaining the hydroethanolic extract of Cereus jamacaru (EHCJ). The phytochemical prospection of the hydroethanolic extract was carried out by liquid chromatography coupled to a mass spectrometer - CLAE-IES-IT-EM/EM to evaluate the presence of flavonoids. In the study of intestinal anti-inflammatory activity, Rattus norvegicus (Wistar), adult females (n = 8/group), weight 230±20, randomly distributed in control groups with 2,4-dinitrobenzene sulfonic acid (DNBS), sulfasalazine 250 mg/kg or EHCJ (50, 100 and 200 mg/kg/day). Clinical parameters (diarrhea, blood in feces, weight loss), macroscopic, microscopic, inflammatory markers such as myeloperoxidase (MPO) enzyme activity, mitogen-activated protein kinase (MAPK), kappa factor beta (NF-kβ p65) were evaluated and cytokines (TNF-α, IL-10 and IL-1β); evaluation of oxidative stress by measuring malondialdehyde (MDA) and the integrity of the intestinal barrier through occludin (OCL). The results of HPLC-EM/EM and IES-IT-EM/EM analysis identified compounds derived from benzoic acid, saccharide, Kampferol-3-O-dirhamnosyl-hexoside, Isorhamnetin-3-O-dirhamnosyl-glycoside, Kaempferol -3-O-rutinoside, Isorhamnetin-3-O-rutinoside and acid oxo-dihydroxy-octadecenoic. In the colitis model, pretreatment with EHCJ at doses of 50, 100 and 200 mg/kg was able to improve the disease activity index, represented by weight loss, diarrhea and blood in the stool (p <0, 05). Furthermore, it reduced the colonic damage induced by DNBS with a reduction in the macroscopic damage score (p<0.05). The treatment reduced MPO enzyme activity (p<0.05) and colonic MDA levels (p<0.01) for all doses tested. The extract also reduced tissue levels of the cytokines TNF-α (p<0.0001) and IL-1β (p<0.05) and increased IL-10 at a dose of 200 mg/kg (p<0.01). The beneficial effect was also demonstrated by the increased expression of OCL protein, involved in epithelial integrity, decreased expression of markers in the MAPK (p<0.01) and NF-kβ (p<0.0001) pathways. Histopathological analyzes show that EHCJ significantly reduced the infiltrate density (p<0.001). Thus, pre-clinical results indicate that EHCJ is a beneficial product in the chemoprevention of colitis and may, in the future, become an alternative in the treatment of human IBD.

 

 

 

 

BANKING MEMBERS:
Presidente - 1544647 - MATHEUS DE FREITAS FERNANDES PEDROSA
Interna - 2578619 - ANA HELONEIDA DE ARAUJO MORAIS
Externa à Instituição - MARIA ELIEIDY GOMES DE OLIVEIRA - UFPB